Pfizer to Shutter Clinical Research Unit in Singapore

By Zachary Brennan

- Last updated on GMT

Pfizer to Shutter Clinical Research Unit in Singapore

Related tags: Clinical trial, Pharmacology, Singapore

As part of wider R&D cuts, Pfizer will close its clinical research unit in Singapore later this year and lay off about 30 employees. 

The closure comes as the company recently ceased research programs in Sandwich, U.K., and relocated research away from its Connecticut base. The cuts in Singapore will not impact Pfizer’s other operations in the country or elsewhere in Asia and laid off employees “may apply for open positions​” elsewhere within the company, spokeswoman Joan Campion told

This decision was made as part of Pfizer Worldwide Research & Development’s ongoing comprehensive effort to increase operational efficiencies and to create a more focused and sustainable R&D engine​,” Campion said.

Established in 2000 and expanded in 2007, the unit is one of three Phase I clinical research facilities operated by Pfizer globally. In 2009, the unit conducted nearly half of all Phase I clinical trials in Singapore, according to the company. The company still has Phase I clinical research facilities in Brussels, Belgium and New Haven, Conn.

Shift to China

The move to shutter a research unit in Singapore might signal a shift away from the island and more toward China.  Pfizer recently set up a joint venture​ with Hisun to develop and manufacture drugs locally in China.

But the push in China comes as other multinational companies ramp up investments in Singapore. Amgen recently announced a $200m investment​ in a biomanufacturing facility there, and Novartis in November also announced a $500m investment​ in a manufacturing facility. In addition, Sanofi and Abbott have regional headquarters in Singapore.

But Pfizer hasn't cut all of its ties to Singapore. The company still has two manufacturing facilities there – one that makes active pharmaceutical ingredients (API) and another that makes nutritional products for infants and children. The API plant is the company’s only API facility in Asia.

Related topics: Clinical Development, Phase I-II

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Related suppliers

Follow us


View more